PhotoMedex to Begin Laser Treatment of Psoriasis Clinical Trials
MONTGOMERYVILLE, Pa., June 23, 2010 — Global skin health solutions company PhotoMedex Inc. announced this month that Dr. John Koo will serve as the principal investigator in a clinical study to assess the efficacy of its Xtrac Velocity excimer laser in the treatment of generalized psoriasis when used in combination with Clobex spray.
Koo’s colleague, Dr. Tina Bhutani will spearhead the study.
When combining the Xtrac Velocity, a laser used to treat psoriasis, with the Clobex spray, a topical agent suitable for use in generalized psoriasis, Bhutani hopes to pioneer an option for treating severe generalized psoriasis with no risk of internal side effects, which are invariably associated with internal agents.
It is anticipated that the combination will reduce the frequency of treatment regimen for psoriasis patients.
In 2008, Koo and his team conducted a successful study with the laser on psoriasis patients who had an affected body surface area (BSA) of 10 to 20 percent. The results of the study helped severe psoriasis sufferers gain access to this technology, said Dennis McGrath, president and CEO of PhotoMedex.
Koo is a professor and vice chairman in the department of dermatology at the University of California San Francisco Medical Center.
For more information, visit: www.photomedex.com
- excimer laser
- A rare-gas halide or rare-gas metal vapor laser emitting in the ultraviolet (126 to 558 nm) that operates on electronic transitions of molecules, up to that point diatomic, whose ground state is essentially repulsive. Excitation may be by E-beam or electric discharge. Lasing gases include ArCl, ArF, KrCl, KrF, XeCl and XeF.
MORE FROM PHOTONICS MEDIA